At the American Society for Microbiology's annual meeting this week, a team of researchers from the University of California, Davis, demonstrated a study showing that silicon nanoparticles they designed could penetrate the blood-brain barrier.
RNAi specialist Alnylam is adding a hepatitis B virus therapy to its pipeline of candidates that employ its Enhanced Stabilization Chemistry-GalNAc-conjugate technology enabling subcutaneous dosing and plans to file an IND by the end of 2015.
Scientists at MIT have engineered a one-two punch for cancer that carries two drugs at a time and has been shown to shrink lung and breast tumors in mice. While other nanoparticles have carried multiple drugs, this one makes use of a specific timing mechanism to get the most out of each treatment.
North Carolina State researchers have developed a method to "smuggle" cancer drugs into cancer cells, enabling delivery of the treatment within the cell itself.
Researchers at Boston College have created a small cage out of metals and organic materials that can act as a "smart" delivery vehicle to carry cancer drugs.
One of the chief drawbacks of RNA interference therapies so far has been the difficulty of delivering small interfering RNA to cells outside the liver. That's why a newly reported breakthrough in delivering siRNA to endothelial cells in the lung and other organs is a big deal.
Tonix Pharmaceuticals has completed enrollment in the 200-patient, placebo-controlled BESTFIT trial of sublingually delivered cyclobenzaprine for the treatment of fibromyalgia.
Boston Scientific rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan, part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth.
Icon Biosciences has advanced its sustained-release therapy for inflammation after cataract surgery to a pivotal late-stage study. With one injection postsurgery, Icon's platform releases anti-inflammatory drugs that currently require multiple topical applications daily.
Clearside Biomedical presented human and animal study data showing the benefits of directly injecting medication into the eye's posterior suprachoroidal space at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
Braeburn Pharmaceuticals received the go-ahead from the FDA to initiate a new clinical trial of implants for the continuous subdermal delivery of buprenorphine to combat opioid dependence.
Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.
Some analysts raised their eyebrows at Oramed's preliminary midstage oral insulin data in late January. Now the Jerusalem company has announced further details of the trial that bring to light a dosing issue, and shares have continued their downward spiral ever since.
Zogenix is selling its Sumavel DosePro Needle-free Delivery System for migraines to Endo International, but don't be fooled--it is maintaining ownership of the delivery technology upon which the product is based.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.
Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.
A team of chemistry professors has developed a method to monitor chemicals as they enter the skin, giving them a better idea of how fast and by which pathways the small molecules permeate the surface.
Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.